Yong Teng
Yong Teng is an expert in Oncology at Emory University (United States). As of October 2026, ScienceLeadR ranks Yong Teng in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck and Carcinoma. Yong Teng has authored 249 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 1,232 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Surgery - Orthopedics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2010 - 2026
Number : 249
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Blueberry Extract Has Anti-Proliferative Activity in Preclinical Models of Head and Neck Cancer. PMID 42702937 — cells, neoplasms, immunotherapy, squamous cell carcinoma of head and neck, carcinogenesis, head and neck neoplasms, therapeutics, mouth neoplasms, wounds and injuries | Head Neck | 2026 | 0 |
| Pancreas-specific lipid nanoparticle-mediated interleukin-10 mRNA delivery ameliorates acute pancreatitis. PMID 42544423 — cytokines, nanoparticles, rna, messenger, biocompatible materials, pancreas, pancreatitis, therapeutics, interleukin-10, lipid nanoparticles | J Mater Chem B | 2026 | 0 |
| Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity. PMID 42289700 — nutrients, neoplasms, food, therapeutics | Exp Hematol Oncol | 2026 | 0 |
| Mitochondrial transfer between tumor and immune cells: a nexus of metabolic adaptation and immune dysfunction. PMID 42277895 — cells, neoplasms, mitochondria, therapeutics | Biomark Res | 2026 | 0 |
| Glycolytic cancer-associated fibroblasts orchestrate metabolic remodeling in the tumor microenvironment. PMID 42271411 — neoplasms, cancer-associated fibroblasts, fibroblasts, therapeutics, tumor microenvironment | J Exp Clin Cancer Res | 2026 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map